(Q38002493)

26 August 2017

title

Ipilimumab in the treatment of melanoma (English)

1 reference

26 August 2017

0 references

Van A Trinh

1

1 reference

26 August 2017

Wen-Jen Hwu

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

14 April 2012

1 reference

Expert Opinion on Biological Therapy

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

6

1 reference

26 August 2017

page(s)

773-782

1 reference

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

CD28 and CTLA-4 coreceptor expression and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Novel therapeutics for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Ipilimumab-induced hypophysitis: MR imaging findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Do we need a different set of response assessment criteria for tumor immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Anti-CTLA-4 antibody adjuvant therapy in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

A methodological framework to enhance the clinical success of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.675325

10.1517/14712598.2012.675325

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference